Showing results 798 to 817 of 918
< previous
next >
| Preview | Issue Date | Title | Author(s) |
| 2021 | Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients | Sallustio, B.C.; Noll, B.D.; Hu, R.; Barratt, D.T.; Tuke, S.J.; Coller, J.K.; Russ, G.R.; Somogyi, A.A. |
| 2003 | Tacrolimus measurement by microparticle enzyme immunoassay II | Taylor, P.; Morris, R. |
| 2004 | TADS study raises concerns | Jureidini, J.; Tonkin, A.; Mansfield, P. |
| 2015 | Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer | Saladores, P.; Muerdter, T.; Eccles, D.; Chowbay, B.; Zgheib, N.; Winter, S.; Ganchev, B.; Eccles, B.; Gerty, S.; Tfayli, A.; Lim, J.; Yap, Y.; Ng, R.; Wong, N.; Dent, R.; Habbal, M.; Schaeffeler, E.; Eichelbaum, M.; Schroth, W.; Schwab, M.; et al. |
| 2015 | Targeting the toll of drug abuse: the translational potential of toll-like receptor 4 | Bachtell, R.; Hutchinson, M.; Wang, X.; Rice, K.; Maier, S.; Watkins, L. |
| 2008 | TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells | Buck, M.; Coller, J.; Murdter, T.; Eichelbaum, M.; Knabbe, C. |
| 2009 | The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio | Bell, J.; Shearer, J.; Ryan, A.; Graham, R.; Korompay, K.; Rizzo, S.; Sindhusake, D.; Somogyi, A. |
| 2001 | The acute cardiovascular effects of 3,4-methylenedioxymethamphetamine (MDMA) and p-methoxyamphetamine (PMA) | Irvine, R.; Toop, N.; Phillis, B.; Lewanowitsch, T. |
| 2002 | The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility | Ali, R.; Awwad, E.; Babor, T.; Bradley, F.; Butau, T.; Farrell, M.; Formigoni, M.; Isralowitz, R.; Boerngen de Lacerda, R.; Marsden, J.; McRee, B.; Monteiro, M.; Pal, H.; Rubio-Stipec, M.; Vendetti, J.; Ali, Robert Leonard |
| 2006 | The assessment of pharmacokinetics in early phase drug evaluation | Rolan, P.; Molnar, V. |
| 2011 | The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes | Zhang, Y.; Vitry, A.; Caughey, G.; Roughead, E.; Ryan, P.; Gilbert, A.; Shakib, S.; McDermott, R. |
| 1997 | The Australian Medicines Handbook and its controlling vocabularies | Walker, D.; Misan, G. |
| 1996 | The cardiovascular protective role of docosahexaenoic acid. | McLennan, P.; Howe, P.; Abeywardena, M.; Muggli, R.; Raederstorff, D.; Mano, M.; Rayner, T.; Head, R. |
| 2005 | The case for strategic international alliances to harness nutritional genomics for public and personal health | Fenech, M. |
| 2015 | The characteristics of a cohort who tamper with prescribed and diverted opioid medications | Larance, B.; Lintzeris, N.; Bruno, R.; Peacock, A.; Cama, E.; Ali, R.; Kihas, I.; Hordern, A.; White, N.; Degenhardt, L. |
| 2005 | The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS) | Ross, J.; Teesson, M.; Darke, S.; Lynskey, M.; Ali, R.; Ritter, A.; Cooke, R. |
| 2010 | The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation | Helsby, N.; Hui, C.; Goldthorpe, M.; Coller, J.; Soh, M.; Gow, P.; de Zoysa, J.; Tingle, M. |
| 2002 | The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine | Kaminskas, L.; Irvine, R.; Callaghan, P.; White, J.; Kirkbride, P. |
| 2009 | The cortical innate immune response increases local neuronal excitability leading to seizures | Rodgers, K.; Hutchinson, M.; Northcutt, A.; Maier, S.; Watkins, L.; Barth, D. |
| 2007 | The cyanobacterial toxin, cylindrospermopsin, induces fetal toxicity in the mouse after exposure late in gestation | Rogers, E.; Zehr, R.; Gage, M.; Humpage, A.; Falconer, I.; Marr, M.; Chernoff, N. |
